Document Detail


Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer.
MedLine Citation:
PMID:  2004379     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lymphocytes isolated from fresh human epithelial ovarian tumors can be expanded in the presence of recombinant interleukin-2, and some CD8 antigen-positive lymphocytes can lyse autologous fresh tumor cells. We treated 7 patients with advanced or recurrent epithelial ovarian cancers, using the adoptive transfer of these tumor-infiltrating lymphocytes (TILs) following a single i.v. injection of cyclophosphamide. One case of disappearance (complete response) and 4 cases of greater than 50% decrease of tumor (partial response) were reported (14.3 and 57.1%, respectively). Regression of tumors in the ovary, liver, lung, and lymph node, both primaries and metastases, lasted for 3-5 months. Furthermore, 10 patients were treated alternately with a cisplatin-containing chemotherapeutic regimen and the adoptive transfer of TILs. Seven cases of complete regression and 2 cases of partial regression of cancer were reported. Four of the 7 patients with a complete response have had no recurrence for greater than 15 months of follow-up. It appears that this experimental technique of adoptive transfer of TILs achieves high response rates even without recombinant interleukin-2 administration and that the prospect of combined therapy using TILs and cisplatin offers hope for increasing the cure rate and long-term survival.
Authors:
Y Aoki; K Takakuwa; S Kodama; K Tanaka; M Takahashi; A Tokunaga; T Takahashi
Related Documents :
9826459 - Prolonged disease-free survival by maintenance chemotherapy among patients with recurre...
24457819 - A prognostic model based on preoperative mri predicts overall survival in patients with...
10785469 - The ability of preoperative serum ca-125 to predict optimal primary tumor cytoreduction...
23078649 - Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patient...
21590259 - Tissue polypeptide specific antigen for early prediction of non-small cell lung cancer ...
16096789 - Pharmacokinetic changes induced by the volume of chemotherapy solution in patients trea...
7521279 - Tumor angiogenesis and rectal carcinoma.
21697679 - Adjuvant chemotherapy for endometrial cancer.
2736109 - Management of malignant lymphoma in the elderly. an eortc retrospective evaluation.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer research     Volume:  51     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  1991 Apr 
Date Detail:
Created Date:  1991-04-23     Completed Date:  1991-04-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1934-9     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Niigata University School of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cisplatin / administration & dosage
Combined Modality Therapy
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Female
Fluorouracil / administration & dosage
Humans
Immunotherapy, Adoptive* / methods
Lymphocytes, Tumor-Infiltrating*
Middle Aged
Ovarian Neoplasms / pathology,  therapy*
Chemical
Reg. No./Substance:
0/CISCA protocol; 15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 51-21-8/Fluorouracil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A fluorine-18 labeled progestin as an imaging agent for progestin receptor positive tumors with posi...
Next Document:  Ganglioside GM3 can induce megakaryocytoid differentiation of human leukemia cell line K562 cells.